sefulness and safety of ultra violet light with stroid cream versus antimalarial tablet with steroid cream in patients of vitiligo.
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2019/07/020345
- Lead Sponsor
- Bankura Sammilani Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Age >=18 yrs to <=85 years
2.Extension of preexisting vitiligo lesion with
in last one year.
3.Appearance of new lesion with in last one
year.
4.Presence of Koëbner phenomenon during the
past 1 year
5.Trichrome or quadrichrome vitiligo
6.No use of any systemic therapy for 4 weeks
prior to enrollment in the study;
7.Informed consent obtained
8.Willing for twice weekly treatment with
narrow band ultraviolet B phototherapy.
1.Childhood vitiligo.
2.Pregnant and lactating women.
3.Patient taking known photosensitizer drugs or
immunosuppressive therapy.
4.Concomitant immune defects, heart disease,
renal failure, malignancy.
5.Patient having retinopathy.
6.Neurological or psychiatric disorders.
7.History of photosensitivity or photo mediated
disorder.
8.Participation in any clinical trial within
the last 3 months
9.Substance or alcohol abuse.
10.Patient having diabetes mellitus.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effectiveness of topical clobetasol with oral hydroxychloroquine versus topical clobetasol with narrow band ultraviolet B (NBUVB) phototherapyTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method To assess the improvement in quality of life with the above mentioned regimeTimepoint: 6 months;To assess the tolerability and safety of the above mentioned regimeTimepoint: 6 months;To estimate the difference in cost incurred for the above mentioned regimeTimepoint: 6 months